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Abstract
Glutamate carboxypeptidase II (GCP II) inhibition has previ-
ously been shown to be protective against long-term neur-
opathy in diabetic animals. In the current study, we have
determined that the GCP II inhibitor 2-(phosphonomethyl)
pentanedioic acid (2-PMPA) is protective against
glucose-induced programmed cell death (PCD) and neurite
degeneration in dorsal root ganglion (DRG) neurons in a cell
culture model of diabetic neuropathy. In this model, inhibition
of caspase activation is mediated through the group II
metabotropic glutamate receptor, mGluR3. 2-PMPA neuro-
protection is completely reversed by the mGluR3 antagonist
(S)-a-ethylglutamic acid (EGLU). In contrast, group I and III
mGluR inhibitors have no effect on 2-PMPA neuroprotection.
Furthermore, we show that two mGluR3 agonists, the direct
agonist (2R,4R)-4-aminopyrrolidine-2, 4-dicarboxylate (APDC)
and N-acetyl-aspartyl-glutamate (NAAG) provide protection to
neurons exposed to high glucose conditions, consistent with
the concept that 2-PMPA neuroprotection is mediated by
increased NAAG activity. Inhibition of GCP II or mGluR3 may
represent a novel mechanism to treat neuronal degeneration
under high-glucose conditions.
Keywords: apoptosis, diabetes, dorsal root ganglia, glutam-
ate carboxypeptidase II, metabotropic glutamate receptor,
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Diabetic neuropathy is a common complication of diabetes,
and occurs in up to 60% of diabetic patients. Despite the
significant pathology associated with nerve degeneration, the
etiology of neuropathy is still unclear. Many pathways may
be involved in diabetic neuropathy, such as oxidative stress
(Cameron et al. 1993; Russell et al. 2002; Vincent et al.
2002), altered polyol metabolism (Cameron et al. 1997),
mitochondrial dysfunction (Montal 1998; Russell et al.
2002; Huang et al. 2003), activation of certain cysteine
proteases (caspases) (Russell et al. 1999, 2002; Srinivasan
et al. 2000; Cheng and Zochodne 2003; Schmeichel et al.
2003), and regulation of growth factors and their interme-
diate signaling pathways (Tomlinson et al. 1996; Sayers
et al. 2003). The glutaminergic system has never been
investigated as a contributing factor to diabetic polyneur-
opathy, although there is considerable evidence that glutam-
ate plays an important role in cellular injury and death in
several neurodegenerative diseases (Arias et al. 1998; Beal
1998; Atlante et al. 2001).
There is increasing evidence that the metabotropic
glutamate receptors (mGluRs) modulate cellular injury
(Vincent and Maiese 2000; De Blasi et al. 2001), although
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the role of the mGluRs in diabetic neuropathy is presently
unknown. The mGluRs are a subfamily of glutamate
receptors that are G-protein-coupled and linked to second
messenger systems (Cartmell and Schoepp 2000; De Blasi
et al. 2001). The eight subtypes are further divided into three
groups based on sequence similarity and second messenger
system coupling. Group I is coupled to phosphoinositide
turnover, groups II and III to adenylate cyclase activity
(Tanabe et al. 1992). mGluR3, as a member of group II, is
negatively coupled to adenylate cyclase, and activation
results in decreased cAMP formation, which may have a
regulatory effect on apoptosis in DRG neurons (Goswami
et al. 2000).
GCP II, previously called NAALADase (N-acetylated
alpha-linked acidic-dipeptidase), is a neuropeptidase
expressed primarily in glial cells that hydrolyzes the
neuropeptide N-acetyl-aspartyl-glutamate (NAAG) into glu-
tamate and N-acetyl aspartate (NAA) (Slusher et al. 1990).
NAAG is both an agonist at group II mGluRs (Wroblewska
et al. 1997) and a mixed agonist/antagonist at the N-methyl-
D-aspartate (NMDA) receptor (Valivullah et al. 1994), and is
released from neurons at depolarization in a calcium-
dependent manner (Tsai et al. 1990). The selective GCP II
inhibitor 2-(phosphonomethyl)pentanedioic acid (2-PMPA)
has been shown to have neuroprotective effects in vitro and
in vivo (Slusher et al. 1999; Thomas et al. 2001) both by
decreasing glutamate formation and by increasing NAAG
concentrations (Slusher et al. 1999; Cai et al. 2002).
This study examines the role of GCP II inhibition in
preventing programmed cell death (PCD) in neurons exposed
to high glucose. In this model, 2-PMPA, a potent and
selective GCP II inhibitor, blocked PCD and promoted
neurite growth in a dose-dependent manner. We also show
that this neuroprotection is mediated through the mGluR3




Sprague-Dawley rats: Harlan-Sprague Dawley (Indianapolis, IN,
USA). ACLAR plastic, Biomedia Gel/Mount: Electron Microscopy
Services (EMS), Ft. Washington, PA, USA. Trypsin, B-27,
neurobasal medium, Dulbecco’s modified Eagles medium (DMEM),
Ham’s F-12 Mix: Gibco-BRL, Gaithersberg, MD, USA. Nerve
growth factor (NGF): Harlan Bioproducts for Science. Pen/Strep/
Neo, l-glutamine, selenium, hydrocortisone, b-estradiol, transferrin,
bisbenzamide, 5-fluoro-2-deoxyuridine (FUDR), N-acetyl-aspartyl-
glutamate (NAAG), adeno cAMP, forskolin, bovine pituitary
extract, fetal bovine serum (FBS): Sigma-Aldrich (St. Louis, MO,
USA). Rabbit polyclonal cleaved caspase-3 antibody: Pharmingen
(San Diego, CA, USA). Alexafluor 596 goat anti-rabbit antibody:
Molecular Probes (Eugene, OR, USA). Caspatag Caspase-9 Cell
Death Detection Kit: Serologicals (Norcross, GA, USA). Apoptag
In Situ Detection Kit, Intergen (Purchase, NY, USA). Protein assay
reagents: Bio-Rad (South San Francisco, CA, USA). Chemilumi-
nescence reagents: Amersham (Piscataway, NJ, USA). Nitrocellu-
lose: Schleicher and Schuell (Keene, NH, USA). Anti-caspase-9
antibody: Cell Signaling (Beverly, MA, USA). Anti-mGluR2/3
antibody: Upstate Biotechnology (Lake Placid, NY, USA). Horse-
radish peroxidase-conjugated goat anti-rabbit and goat anti-mouse
antibodies: Santa Cruz (Santa Cruz, CA, USA). Anti-GAPDH
antibody: Chemicon (Temecula, CA, USA). 2- (Phosphonometh-
yl)pentanedioic acid (2-PMPA) and 2-[phosphonomethyl] succinic
acid (2-PMSA) provided by Guilford Pharmaceuticals (Baltimore,
MD, USA). The mGluR inhibitors group I receptor antagonist
(RS)-1-aminondan-1,5-dicarboxylic acid (AIDA), group II antagon-
ist (S)-a-ethylglutamic acid (EGLU), the group III antagonist
a-methylserine-O-phosphate (MSOP), and the group II agonist
(2R,4R)-4-aminopyrrolidine-2,4-dicarboxylate (APDC): Tocris
Cookson Inc (Ellisville, MO, USA).
Cell culture
DRG-Schwann cell (DRG-SC) co-culture
DRG-SC co-cultures were prepared as previously described with the
exception that SC were not removed from the culture (Russell et al.
1999, 2002; Vincent et al. 2002). All DRG were grown with
endogenous SC, except where otherwise noted, because SC are
necessary for the neuroprotective effects of GCP II inhibition and
mGluR3 activation (Bruno et al. 1997; Slusher et al. 1999; Moldrich
et al. 2001; Thomas et al. 2001). Briefly, DRG from 15-day-old
embryonic (E15) Sprague-Dawley rats were aseptically plated on air-
dried, collagen-coated plastic ACLAR dishes or collagen coated glass
cover slips. Dissociated DRG were prepared by incubating whole
DRG containing SC in 0.25% trypsin for 40 min at 37C, centrifuging
at 800 · g for 5 min, and then removing trypsin. Explant cultures
were grown by placing whole DRG containing SC onto collagen-
coated prehydrated aclar dishes. Co-cultures were initially grown for
4–5 days (dissociated) or 1 day (explant) in neurobasal medium
containing 25 mM glucose (optimal basal glucose for neurons)
(Russell and Feldman 1999; Russell et al. 1999; Srinivasan et al.
2000), with 0.5% B27, 10 ng/mL nerve growth factor, 0.5% Pen/
Strep/Neo, and 1.4 mM l-glutamine. Before experimental conditioned
media was added, cells were rinsed three times with low phosphate
DMEM, and then defined, serum-free medium was added. Defined
medium contains DMEM supplemented with 1.4 mM l-glutamine,
30 nM selenium, 10 nM hydrocortisone, 10 nM b-estradiol, and
10 lg/mL transferrin. For all experiments containing 2-PMPA, media
containing low phosphate was used as physiological concentrations of
phosphate may inhibit GCP II activity (Thomas et al. 2000). It was
previously determined that low-phosphate medium does not induce
neuronal death (data not shown).
Pure DRG culture
Pure DRG cultures were prepared in the same manner as DRG-SC
co-cultures, however, initial plating media contained 40 lM FUDR,
and FUDR treatment was maintained until the cultures were
depleted of SC and fibroblasts.
Pure differentiated SC cultures
SC were collected from the sciatic nerve of day 3 postnatal Sprague-
Dawley rat pups, as previously described (Brockes et al. 1980;
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Delaney et al. 1999). Pure SC cultures were maintained in growth
medium containing DMEM, 10% FBS, 2 lM forskolin, and
20 lg/mL bovine pituitary extract. Upon 80% confluency SC were
differentiated in DMEM with 10% FBS and 100 lM adeno cAMP.
After 24 h incubation, cells were rinsed in DMEM, and conditioned
medium added in serum-free Schwann cell differentiation medium
(SCDM), containing 50% Ham’s F-12 Mix, 50% low-glucose
DMEM, and 1 · B27 supplement.
Immunohistochemistry
Caspase-3 cleavage
Cultures were fixed after the experimental time point for 30 min
with 4% paraformaldehyde in phosphate-buffered saline (PBS), and
then stained for active caspase-3 as previously described (Russell
et al. 1999; Russell et al. 2002; Vincent et al. 2002). Cultures were
incubated in 0.5 lg/mL rabbit polyclonal cleaved caspase-3
antibody for 2 h at 37C. Cells were then incubated in 5 lg/mL
Alexafluor 596 goat anti-rabbit antibody at room temperature for
1 h. Specificity and concentration of the anti-active antibody was
determined by immunoadsorption against cleaved peptide. Samples
were then co-stained with 1 lg/mL bisbenzamide in PBS for 5 min
at room temperature. The bisbenzamide permits DRG and SC nuclei
to be easily and separately identified. Cells were finally mounted on
slides with Biomedia Gel/Mount, and analyzed at 40· magnification
on a Zeiss Axiophot microscope by a blinded observer in a random
fashion. For each slide, 10 random fields of 25–100 cells per field
were counted, and the percent caspase-3 positive neurons were
determined. The percentages for each field were averaged for each
condition. Each experiment was repeated a minimum of three times.
Caspase-9 cleavage
Caspase-9 cleavage was assayed in DRG-SC co-cultures using a
Caspatag caspase-9 Cell Death Detection Kit. The protocol was
followed for adherent cells as previously described (Russell et al.
2002). Briefly, conditioned media was added for 2 h alone, and then
caspase-9 antibody was added to conditioned media for 1 h. Cells
were counterstained with bisbenzamide, and then fixed in 4%
paraformaldehyde for 30 min. Cells were analyzed in the same
manner as anti-caspase-3 stained cells.
Neurite outgrowth
Cultured DRG explant cultures were grown for 1 day with
endogenous SC, and then exposed to experimental conditioned
media. Measurements were obtained every 24 h on a Leitz
microscope at 5 or 10· magnification, as previously described
(Russell et al. 1994) by a trained observer blinded to the
experimental condition. Briefly, the longest neurite from each of
24 explants per condition was measured each day for the specified
number of days, with baseline growth at the start of the experiment
being defined as 0 mm. Results were standardized against control
conditions. Each experiment was repeated a minimum of 3 times.
TdT-mediated dUTP-biotin nick end labeling (TUNEL)
staining
DRG-SC co-cultures were fixed in 4% paraformaldehyde for 20 min
and then TUNEL stained using the Apoptag In Situ Detection Kit to
detect nuclear fragmentation, as previously described (Delaney
et al. 2001). Slides were analyzed at 100· on a Zeiss Axiophot
microscope by a blinded observer in a random fashion; for each
slide, 10 random fields of 25–100 cells each were counted, and the
percent TUNEL positive neurons determined for each field. The
percentages for each field were averaged for each condition. Each
experiment was repeated a minimum of 3 times.
Immunoblot detection of mGluR3 and caspase-9 protein
Western immunoblot was performed as previously described
(Delaney et al. 2001; Vincent et al. 2002). Protein (25 lg per
sample) was separated by SDS-PAGE and transferred to nitrocel-
lulose. Primary antibody was diluted 1 : 1000 (antiactive caspase-9)
or 1 : 500 (anti-mGluR2/3), followed by secondary horseradish
peroxidase-conjugated goat anti-rabbit antibody diluted 1: 2000.
After exposure using chemiluminescence reagents, the blot was
re-probed for GAPDH at a 1 : 2000 dilution, followed by
horseradish peroxidase-conjugated goat anti-mouse antibody at a
1 : 2000 concentration.
Drug treatment
Before beginning experimental drug treatment, DRG-SC co-cultures
or pure DRG neuronal cultures were grown for 4–5 days (dissoci-
ated cultures) or 1 day (explant cultures) at 37C. Before addition of
drugs, cells were rinsed three times with low phosphate DMEM. All
drugs were added simultaneously except in the case of experiments
using EGLU and NAAG, in which case any condition with EGLU
was subjected to 30-min pretreatment with EGLU. For all other
experiments, it was determined that drug pretreatment did not affect
the results from receptor blocking or activation. Cells were not kept
in conditioned media for longer than 24 h without re-dosing with
fresh media.
Statistics
Due to the large number of data points measured, a normal
distribution for each of the endpoints was assumed. Overall
changes in measures were analyzed using ANOVA, and individual
comparisons were made using Student’s t-test and assuming
unequal variances. Levels of significance are as follows: p < 0.05
(*), p < 0.01 (**), and p < 0.001 (***) and comparisons are made
with control, except where otherwise noted. For graphical and
descriptive purposes data are presented as mean ± standard error of
the mean (SEM). In some cases, results were standardized against
controls.
Results
2-PMPA prevents glucose-induced PCD
In order to establish that PCD is induced in a combined
system, DRG-SC co-cultures were treated with 20 mM added
glucose (45 mM total glucose). The percentage of neurons
positive for cleaved caspase-3 and TUNEL staining were
increased by high-glucose (Fig. 1). Control neurons show
lower cell death than in previous SC free studies (Russell and
Feldman 1999; Russell et al. 1999), suggesting that the
presence of SC reduces PCD.
The GCP II inhibitor 2-PMPA was examined in both
control and glucose-treated cells to determine if it could
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rescue DRG neurons from glucose-induced PCD. Three
separate PCD assays, caspase-3 and -9 cleavage and TUNEL,
all showed that 2-PMPA is able to completely rescue DRG
neurons from glucose-induced PCD. 2-PMPA is able to
completely rescue DRG neurons from caspase-3 cleavage for
up to at least 24 h (Fig. 1a), and DNA fragmentation up to at
least 48 h (Fig. 1b). It was determined from our own dose-
response experiments and published results (Slusher et al.
1999) that the optimal concentration of 2-PMPA in culture to
prevent PCD is 6 lM. There is increasing toxicity above this
optimal dose. SC are in general less susceptible to glucose-
induced damage than are DRG neurons (Delaney et al.
2001), but are able to prevent neuronal injury, making them
an ideal target for GCP II inhibition.
In order to ascertain that 2-PMPA inhibition was specific
for GCP II, the inactive analogue 2-PMSA was tested as a
potential inhibitor of glucose-induced cell death. As was
expected, 2-PMSA had no ability to rescue DRG from PCD
within the co-culture system (Fig. 1c). Neither 2-PMPA nor
EGLU alone had any effect on caspase-3 cleavage or
TUNEL activation (data not shown).
mGluR3 antagonists are able to reverse neuroprotection
provided by 2-PMPA
One protective effect of 2-PMPA is hypothesized to be
increased action of NAAG at the mGluR3 receptor. We
therefore tested whether an mGluR3 antagonist along with
2-PMPA would block 2-PMPA mediated neuroprotection in
this system. For comparison, we also used several other
mGluR antagonists. We found that the mGluR3 antagonist
EGLU was able to reverse protection provided by 2-PMPA
in all 3 PCD assays used: caspase-3 and -9 cleavage, and
TUNEL (Figs 1 and 2). The addition of the mGluR3
antagonist EGLU reversed the protection provided by
2-PMPA in all instances. However, this reversal of protec-
tion was not seen with the group I mGluR antagonist
AIDA, nor the group 3 mGluR antagonist MSOP. However,
when all three mGluR3 antagonists were combined (AIDA,
MSOP, and EGLU), reversal of protection was seen once
again (Fig. 1). All antagonists were added at an identical
concentration of 100 lM, sufficient to block their specific
receptors.
Similar to previous observations in DRG neurons,
caspase-9 cleavage occurs early in the PCD cascade with
maximal cleavage at 3 h (Russell et al. 2002), as shown in
Fig. 2(a).
The caspase-9 immunoblot showed similar results to
immunohistochemistry (Fig. 2b). In general, immunoblotting
is less sensitive than immunohistochemistry in DRG-SC
co-cultures, due to the relatively large proportion of SC
protein (with considerably less cleaved caspase-9) compared
to DRG protein. However, the immunohistochemical results
in co-cultures, which permit measurement of PCD in DRG
alone, were confirmed with immunoblotting for caspase-9
protein up-regulation and cleavage. The immunoblot shows
an increase in both total caspase-9 protein levels as well as an
increase in the 37 kDa cleavage product, showing
up-regulation of caspase-9 in glucose-treated cells as com-
pared to cells treated with glucose and 2-PMPA combined.
Fig. 1 2-PMPA prevents glucose-induced PCD at 24 h as indicated by
the percent neurons positive for cleaved caspase-3 (a) and at 48 h as
indicated by TUNEL positive nuclei (b). Cells were treated with 20 mM
added glucose ± 6 lM 2-PMPA, or ± 100 lM of one or more mGluR
antagonist. The mGluR3 antagonist EGLU was able to reverse the
neuroprotective effects of 2-PMPA, both alone and in conjunction with
group I and group III antagonists. Neither the group I antagonist AIDA,
nor the group III antagonist MSOP was able to reverse 2-PMPA pro-
tection. Ten micromoles of the inactive analogue 2-PMSA does not
inhibit glucose-induced cell death (c). ***p < 0.001.
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The ratio of caspase-9 cleavage product to GAPDH was
ninefold higher with added glucose than control. In contrast,
the caspase-9 cleavage product was reduced in the presence
of 2-PMPA and increased by addition of EGLU using both
immunohistochemistry and immunoblotting. As with added-
glucose alone, there was an increase in total caspase-9 levels
in the presence of EGLU.
2-PMPA promotes neurite growth in the presence of
elevated glucose concentrations
In order to assess the effect of 2-PMPA on glucose-induced
axonal degeneration and slowed growth, mean neurite
growth of explant DRG-SC co-cultures were measured. In
the presence of added glucose, there was an overall
reduction in neurite growth (Fig. 3a) at all time points
compared to control (p < 0.001), as well as degeneration of
neurites with continued exposure to glucose (Fig. 3b). In
contrast, 2-PMPA maintained normal neurite growth and
viability in high glucose conditions. The mGluR3 antago-
nist EGLU blocked this 2-PMPA mediated effect at all time
points (p < 0.001). Observed differences continued to 72 h
(data not shown). Neither the group I antagonist AIDA, nor
the group III antagonist MSOP, were able to reverse
2-PMPA preservation of neurite growth under high glucose
conditions. 2-PMPA alone and EGLU alone had no effect
on neurite growth compared to control (data not shown).
NAAG is neuroprotective against PCD
Because it is believed that 2-PMPA’s neuroprotective effects
stem at least in part from NAAG’s agonist activity at the
mGluR3 receptor (Slusher et al. 1990; Wroblewska et al.
1993, 1997; Neale et al. 2000), we determined if NAAG
directly prevented glucose induced PCD. We added 100 lM
NAAG to cells treated with added glucose, and measured
both caspase-3 cleavage (Fig. 4a) and TUNEL assays
(a)
(b)
Fig. 3 2-PMPA is able to promote DRG explant neurite growth (DRG-
SC co-cultures) in the presence of glucose. Neurite growth in mm (a)
and light micrographs showing neurite length and density (b) at low
(i–iii) and high (iv–vi) magnifications. Explants plated in the presence
of glucose (ii and v) have shorter and sparser neurites, or show
evidence of neurite beading and degeneration compared to control
explants (i and iv). Six micromolar 2-PMPA promotes growth in the
presence of 20 mM glucose (iii and vi). 2-PMPA is able to reverse the
effects of glucose on rate of neurite growth, an effect that is partially
inhibited by the mGluR3 antagonist EGLU. Neither the group I ant-
agonist AIDA nor the group II antagonist MSOP had any effect on
2-PMPA protection. 2-PMPA alone had no effect on growth (data not
shown).
Fig. 2 Immunohistochemistry (a) and immunoblot (b) for caspase-9
activation show an increase in caspase-9 activation at 3 h after
addition of extra glucose. In the immunoblot, both the 51 kDa
caspase-9 zymogen and the 40 kDa cleavage product are increased
with added glucose (25 lg protein loaded per lane) at 3 h. Caspase-9
cleavage is partially reversed by the group II mGluR antagonist EGLU.
Cells were treated with 20 mM glucose ± 6 lM 2-PMPA, or ± 100 lM
EGLU. The housekeeping protein GAPDH was detected at 35 kDa on
the same blot and shows equal protein loading in each lane. The ratio
of caspase-9 cleavage product to GAPDH is shown above the GAPDH
blot. *p < 0.05.
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(Fig. 4b). NAAG reduced glucose-induced caspase-3 and
TUNEL activation, and EGLU was able to reverse protec-
tion, indicating that NAAG is acting through mGluR3.
NAAG alone had no effect on neuron survival.
NAAG promotes neurite growth in the presence of
elevated glucose concentrations
In order to ascertain that NAAG promotes neurite growth in
the presence of elevated glucose, neurite growth was
measured for DRG explants for 72 h (Fig. 5). In the presence
of glucose, neurite growth was slowed compared to control at
all time points (p < 0.001), however, NAAG was able to
reverse this trend. The mGluR3 antagonist EGLU blocked
NAAG protection (p < 0.001 compared to control). Neither
NAAG nor EGLU alone had a significant effect on neurite
growth as compared to control (data not shown).
The selective mGluR3 agonist APDC is able to prevent
glucose-induced PCD
In order to determine that 2-PMPA’s and NAAG’s neuro-
protective effects result from agonist activity at the mGluR3
receptor, a selective mGluR3 agonist was examined as a
potential inhibitor of PCD. We found that APDC was able to
prevent glucose-induced PCD, and was reversed by EGLU
(Fig. 6). APDC alone had no significant effect. This result
demonstrates that a known mGluR3 agonist produces similar
effects to NAAG and 2-PMPA.
mGluR3 agonists are not protective in the absence of SC
To determine if SC are necessary for mGluR3 neuroprotec-
tion, we tested whether 2-PMPA, NAAG, or APDC provided
protection against glucose-induced cell death in DRG
Fig. 5 NAAG is able to promote neurite outgrowth in the presence of
20 mM added glucose over a time period of 72 h. This effect is com-
pletely inhibited by the mGluR3 antagonist EGLU, suggesting that
NAAG-mediated prevention of slowed axonal growth is mediated
through mGluR3. NAAG alone had no effect on growth (data not
shown).
Fig. 4 100 lM NAAG is neuroprotective against glucose-induced cell
death as measured by the percentage of neurons positive for cleaved
caspase-3 at 24 h (a) and TUNEL at 48 h (b). The mGluR3 antagonist
EGLU is able to reverse the effects of NAAG, suggesting that NAAG
neuroprotection is mediated through the mGluR3 receptor. NAAG
alone has no effect on caspase-3 activation. **p < 0.05, ***p < 0.001.
Fig. 6 The selective mGluR3 agonist APDC is neuroprotective
against 20 mM added glucose. At a concentration of 100 lM, APDC
prevents PCD as measured by the percent neurons positive for
TUNEL. The mGluR3 antagonist EGLU is able to reverse protection
afforded by APDC. ***p < 0.001.
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neurons in the absence of SC (Fig. 7). We found that none of
the three agents provided protection, indicating that glial-
neuronal signaling is crucial for mGluR3-mediated neuro-
protection.
mGluR3 is expressed in SC but not DRG neurons
In order to determine if mGluR3 is located on SC or DRG,
lysates from DRG-SC co-cultures, as well as pure DRG
cultures and pure differentiated SC cultures, were analyzed
for mGluR3 receptor. Immunoblotting revealed that mGluR3
protein is present in pure SC cultures, and to a lesser extent in
DRG-SC co-cultures, but could not be detected in DRG
neurons (Fig. 8). This data implies that the receptor is found
on SC rather than DRG neurons.
Discussion
Although the glutaminergic system has been implicated in
many neurological disorders, including ischemic brain
injury, Parkinson’s disease, and Alzheimer’s disease (Arias
et al. 1998; Beal 1998; Atlante et al. 2001), its role in the
pathogenesis of diabetic neuropathy is uncertain. This
study indicates a possible regulatory mechanism through
GCP II enzymatic cleavage of NAAG into NAA and
glutamate. Inhibition of GCP II cleavage of NAAG by
2-PMPA blocks glucose-induced cell death in DRG
neurons, an effect that is likely mediated through NAAG
agonist activity at mGluR3.
PCD has been characterized in vitro by caspase-3 and -9
cleavage, TUNEL staining, and transmission electron micr-
oscopy, and shows evidence consistent with neuronal injury
and mitochondrial dysfunction (Russell et al. 1999, 2002;
Srinivasan et al. 2000. Similar changes are observed in vivo
in acute and chronic streptozotocin diabetic rat DRG (Russell
et al. 1999; Srinivasan et al. 2000; De Giorgi et al. 2002;
Schmeichel et al. 2003). Previous studies both in this
laboratory and by other groups indicate that cultured
neurons, in contrast to non-neuronal cells, require higher
basal concentrations of glucose (Korinkova and Lodin 1976;
Bottenstein et al. 1989; Russell et al. 1999, 2002), and that
concentrations of glucose in culture greater or less than
25 mM induce a dose-dependent cleavage of caspase-3 and
increase in TUNEL staining (Russell et al. 1999, 2002),
likely through rapid ATP depletion. This relatively high
concentration of basal glucose most likely reflects the
increased energy requirements and metabolic rate of DRG
compared to non-neuronal cells.
In our current DRG-SC co-culture system, PCD in control
conditions was approximately 1–3%, which differs from 7 to
15% in DRG cultures with no endogenous SC (Russell et al.
1999). This finding is not surprising, as the glial cells likely
have neuroprotective effects on neurons, particularly during
development or following toxic injury (Davies 1998; Mold-
rich et al. 2001). Furthermore, we have shown that glial cells
are necessary in the neuroprotective mechanisms mediated
by inhibition of GCP II and NAAG. Several other groups of
investigators have found glia to be necessary for mGluR3
activation to be neuroprotective to neurons (Bruno et al.
1997; Slusher et al. 1999; Moldrich et al. 2001). This is
(a)
(b)
Fig. 8 mGluR3 receptor is localized on SC rather than DRG. Pure
DRG neuron cultures show no immunoreactivity to anti-mGluR2/3
antibody, while 100 kDa bands corresponding to mGluR3 are seen in
DRG-SC co-cultures and pure SC cultures (a). A histogram showing
the ratio of mGluR2/3 : GAPDH housekeeping protein indicates that
immunoreactivity for mGluR2/3 is higher in pure SC cultures than in
DRG-SC co-cultures (b), implying that the mGluR3 receptor is located
on SC rather than on DRG neurons.
Fig. 7 2-PMPA, NAAG and APDC do not protect DRG neurons grown
without SC. Glucose-induced cell death was measured by percent
neurons positive for cleaved caspase-3 at 24 h. This suggests that SC
are necessary for mGluR3-mediated neuroprotection. ***p < 0.001.
96 A. Berent-Spillson et al.
 2004 International Society for Neurochemistry, J. Neurochem. (2004) 89, 90–99
likely due to the presence of mGluR3 on glia rather than
neurons. Similar to previous findings (Azkue et al. 2000), it
is hypothesized that mGluR3 activation induces the release
of neuroprotective factors from the glia, such as NGF
(Ciccarelli et al. 1999), TGFb (Bruno et al. 1998; Thomas
et al. 1999a; Aronica et al. 2000; D’Onofrio et al. 2001), or
S-100b (Ciccarelli et al. 1999), and indirectly protects
neurons from PCD. Thus, a DRG-SC co-culture system
was used in these experiments, rather than purified DRG
neurons as in our previous studies (Russell et al. 1998, 1999,
2002; Vincent et al. 2002).
GCP II is inhibited both by 2-PMPA and by cell culture
medium containing physiological levels of phosphates
(Thomas et al. 2000). There is some evidence that diabetic
patients may have lower than normal blood phosphate levels
(Ravenscroft et al. 1999), thus in diabetic patients GCP II is
likely to be active and to mediate glucose-induced neuronal
PCD. 2-PMPA neuroprotection was completely reversed by
the group II antagonist EGLU, while groups I and III
antagonists had no effect on protection, indicating that
2-PMPA neuroprotection is mediated via the mGluR3
receptor. This is likely due to increased NAAG concentra-
tions, as 2-PMPA inhibits GCP II hydrolysis of NAAG. In
order to determine that 2-PMPA is not preventing glucose-
induced PCD via non-selective inhibition of GCP II, an
inactive analogue 2-PMSA was used (Thomas et al. 2001).
2-PMSA failed to either block GCP II or protect against
glucose-mediated PCD, leading to the conclusion that the
neuroprotection afforded by 2-PMPA is both selective and
specific in this system.
In addition to preventing PCD, 2-PMPA promotes neurite
outgrowth in neurons treated with added glucose. DRG
neurites treated with increased glucose had a reduced rate of
growth compared to controls, neurite density was reduced, and
neurites showed evidence of degeneration. These changes
were similar to those observed in rat sensory neurons in vivo
(Russell et al. 1999). In contrast, 2-PMPA reversed glucose-
induced inhibition of neurite growth. Thus the protective
effects of 2-PMPA extend beyond cell survival to cell growth.
Because the link between mGluR3 and 2-PMPA neuro-
protection was so profound, we determined if selective
mGluR3 agonists were able to provide the same sort of
neuroprotection. One such agonist, NAAG, is increased by
2-PMPA inhibition of GCP II (Slusher et al. 1999), and
furthermore is an endogenous agonist at the mGluR3
receptor (Wroblewska et al. 1993, 1997; Neale et al.
2000). NAAG has been shown to be neuroprotective in a
variety of neurological disorders (Thomas et al. 2001; Cai
et al. 2002), and this study showed it to be protective against
glucose-induced PCD, able to completely reverse glucose-
induced cell death at every time point tested. In addition,
NAAG prevented glucose-induced inhibition of neurite
growth in explant cultures. This effect was partially blocked
by an mGluR3 antagonist. These findings indicate that
NAAG is critical in mediating 2-PMPA neuroprotection in
this model of diabetic neuropathy.
Supporting the concept that NAAG neuroprotection is
mediated via mGluR3, the selective agonist APDC was able
to completely reverse glucose-induced PCD, while the
mGluR3 inhibitor EGLU blocked this effect. This finding
that mGluR3 agonist activity alone is sufficient to prevent
glucose-induced PCD is consistent with the concept that in
this high glucose system, NAAG agonist activity at mGluR3
is neuroprotective.
In summary, high-glucose conditions in DRG-SC
co-cultures results in increased caspase-3 and -9 cleavage,
TUNEL-positive nuclei indicating nuclear degradation, and a
decreased neurite growth rate. These effects are blocked in a
dose-dependent manner by the GCP II inhibitor, 2-PMPA.
Prevention of PCD by 2-PMPA is specific, and is mediated at
least in part by the mGluR3 receptor. This is indicated by
reversal of protection with the mGluR3 antagonist EGLU,
neuroprotection afforded by the mGluR3 agonist APDC, and
the neuroprotective effects of NAAG. As 2-PMPA prevents
hydrolysis of NAAG into is subcomponents, our findings
support the concept that 2-PMPA neuroprotection is medi-
ated by NAAG’s agonist activity at the mGluR3 receptor.
These results support the hypothesis that hyperglycemia
induces GCP II hydrolysis, and have important pharmaco-
logic implications for future therapy of diabetic neuropathy.
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